← All trials
NCT03581305
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 20, 2018
- Primary completion
- Apr 6, 2022
- Completion date
- Apr 6, 2022
- First posted
- Jul 10, 2018
- Last posted
- Mar 21, 2023
- Enrollment
- 46
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institutes of Health (NIH)Lead sponsor
- National Institutes of Health (NIH)Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.